Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

List today: American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

Kahn serves as an advisory panel member/consultant for Abarceo Pharma, Amgen, AltPep, Anji, Biomea Fusion, Eli Lilly and Company, Merck, Neurimmune, Novo Nordisk, and Oramed and receives research ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Corcept's Phase 3 GRADIENT trial for relacorilant has missed its primary endpoint – the improvement in SBP for Cushing's ...

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, ...

The federal government is committed to helping small and medium-sized businesses bring their innovations to life from coast to coast to coast and ensuring that people can benefit from their creative ...

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 27 cents per share. The drug developer posted revenue of $182.5 million in the period, which also beat ...